Global biopharmaceutical Abbvie said Monday it has ranked number one, for two years in a row, on the Dow Jones Sustainability Index (DJSI) for the biotech industry.
Abbvie에브비 presented a slew of good news in the past week with favorable results from a phase 2 trial for its eczema (atopic dermatitis) treatment. Industry experts also say Abbvie’s grip on Humira patents that has hindered competitors such as Coherus BioScience from challenging its blockbuster biologic has contributed to the boost.
The company’s shares have also soared, gaining 37 percent this year and rising 14 percent in the last week alone.
In the DJSI, Abbvie earned the highest scores among 40 biotech companies, recording the top marks on 13 out of the total 25 evaluative criteria, the company said. Notably, it gained full marks in environmental reporting and policy influence. Marks in categories such as work behavior index and human resource development also rose 15 points compared with last year, the company said.
DJSI is a global benchmark index to evaluate about 3,900 companies based on environmental, societal efforts and corporate integrity, the company said.
“Our innovative efforts are not confined to treatments only by exerting a larger influence on society. As a patient-centered company, we believe we need to create harmony between robust research and a strong commitment to the regional community,” said Abbvie Chairman and CEO Richard A. Gonzales. “Abbvie would like to extend a sign of gratitude to the acknowledgment of the DJSI and continually work toward improving sustainability.”
<© Korea Biomedical Review, All rights reserved.>